CoV-2 mRNA Vaccine / eTheRNA immunotherapies - LARVOL DELTA

eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations (PRNewswire) - “eTheRNA Immunotherapies nv…announced that a consortium has been formed with North American and European partners to develop a novel mRNA vaccine against CoV-2 and preclinical development has started. Chinese partners may be added in the consortium in due course…eTheRNA and its partners EpiVax, Nexelis, REPROCELL and CEV* have extensive experience in the mRNA vaccine field and this will help accelerate progress towards clinical trials with patient enrolment expected in early 2021.”

Enrollment status • Licensing / partnership • New trial